Precision and Accuracy in Lipidomics Research
Lipid analysis by liquid chromatography-mass spectrometry (LC-MS) is challenging due to their complexity as a class of molecules and their highly isobaric and isomeric nature. Without proper sample preparation, up-front separation strategies, internal standards, and intelligent acquisition and processing software, the mass analysis and data interpretation can be problematic. Over the years, numerous techniques have been developed to address these challenges, but until recently, there was no commercially available start-to-finish turn-key solution for lipidomics for the non-experienced user or the novice to the field.
The Lipidyzer™ Platform is a complete package for lipidomics analysis that can differentiate and quantify more than 1100 lipid molecular species across 13 lipid classes validated in human serum and plasma in a fully-automated solution that takes you from samples to results in as little time as possible. The platform includes a robust mass spectrometer utilizing differential mobility separation technology (DMS), novel labeled internal standards and software to wrap up and automate the entire workflow. The system benefits include specificity, absolute quantitation and comprehensive coverage of complex lipid metabolism.
To validate the precision, accuracy, and reproducibility of the platform, a commercially available control sample was analyzed over the course of 5 days. The study involved 4 Lipidyzer platforms across 3 different laboratories. As shown in the figure below, the instruments detected and quantified similar numbers of lipid species across all instruments and days, with similar precision. For this particular sample, over 675 lipid species were routinely detected and quantified with RSD <20%, and many with even lower % RSD. Because lipids are so challenging to analyze, this high level of precision has historically not been routinely observed with other methodologies, and thus, is quite impressive for the Lipidyzer Platform.
Besides this control sample, other biological studies have been run to validate the platform and demonstrate its use as a valuable tool for studying lipids in disease. For example, using the Lipidyzer Platform, researchers were able to validate lipid changes in preeclamptic women, characterize lipids in hypertriglyceridemia and hypercholesterolemia patients, study lipid distribution in a weight loss study, and characterize lipids in an age-related study, comparing results to the traditional discovery lipidomics workflow.
To learn about these studies and see the Lipidyzer Platform in action, see the recent webinar The Lipidyzer Platform: A Revolutionary Tool for Understanding the Role of Lipids in Disease. Additionally, to learn more about the powerful techniques that the Lipidyzer Platform brings together to tackle the challenges of lipid analysis and make lipidomics routine, read our interview with Steve Watkins, Ph.D., CTO Metabolon, and read our more in-depth blog discussing the key attributes of the Lipidyzer Platform.